Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer

Pathology Research and Practice

Volumn 207, Issue 8, 2011, Pages 468-471

  Egervari, Kristof ^a   Kosa, Csaba ^a   Szollosi, Zoltan ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Borsod County Teaching Hospital   (Hungary)

Author keywords

Breast cancer; Chromosome17; HER2; Polysomy

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CENTROMERE; CHROMOSOME 17; CONTROLLED STUDY; CORRELATIONAL STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; KARYOTYPING; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SCORING SYSTEM; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR BIOLOGY;

EID: 80051789905     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.05.008     Document Type: Article

References (12)

1. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
2. Watters A.D., Going J.J., Cooke T.G., Barlett J.M. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res. Treat. 2003, 77:109-114.
3. Moelans C.B., de Weger R.A., van Diest P.J. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res. Treat. 2010, 120:1-7.
4. Marchio C., Lambros M.B., Gugliotta P., Di Cantogno L.V.D., Botta C., Pasini B., Tan D.S.P., Mackay A., Fenwick K., Tamber N., Bussolati G., Asworth A., Reis-Fiho J.S., Sapino A. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009, 219:16-24.
5. Viale G. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J. Pathol. 2009, 219:1-2.
6. Yeh I.T., Martin M.A., Robetorye R.S., Bolla A.R., McCaskill C., Shah R., Gorre M.E., Mohammed M.S., Gunn S.R. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Modern Pathol. 2009, 22:1169-1175.
7. Dowsett M., Hanna W.M., Kockx M., Penault-Liorca F., Gutjhar T., Habben K., van de Vijver MJ M.J. Standardization of HER2 testing: results of an international proficiency-testing ring study. Modern Pathol. 2007, 20:584-591.
8. Press MF M.F. How is Her2 status established when HER2 and chromosome 17 centromere are both amplified?. Am. J. Clin. Pathol. 2006, 126:673-674.
9. Troxell M.L., Bands C.D., Lawce H.J., Galperin I.B., Baiyee D., West R.B., Olson S.B., Cherry A.M. Evaluation of HER2 status in carcinomas with amplified chromosome 17 centromere status. Am. J. Clin. Pathol. 2006, 709-716.
10. Tuma R.S. Inconsistency of HER2 test raises questions. J. Natl. Cancer Inst. 2007, 99:1064-1065.
11. Gunn S., Yeh I.T., Lytvak I., Tirtorahardjo B., Dzidic N., Zadeh S., Kim J., McCaskill C., Lim L., Gorre M., Mohammed M. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 2010, 10:396-404.
12. Gunn S.R., Gorre M.E., Mohammed M.S., McCaskill C., Hibbard M.K., Barry T.S., Yeh I.T. Validation of an array CGH test for HER2 status using tumor targeted DNA extraction from formalin fixed tissue: comparison with frozen tissue results. Cancer Res. 2009, 24:835S.